Once-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in ONWARDS 5 phase 3a trial
Novo Nordisk bolstered by another late-stage trial of once weekly insulin icodec (NVO) | Seeking Alpha
Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing | BMJ Open Diabetes Research & Care
Novo Nordisk's icodec therapy delivers positive data - PharmaTimes
Novo Scores Phase III Insulin Icodec Win, Potentially Strengthening Market Position | BioSpace
Novo Nordisk to file for regulatory approval of once-weekly insulin icodec next year
Novo Nordisk Once-weekly Insulin Icodec Shows Comparable Efficacy To Once-daily Insulin Glargine U100 in Phase 2 trial
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduct
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Novo Nordisk 2022: Expanding capabilities – PharmaLive
Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes - Philis‐Tsimikas - Diabetes, Obesity and Metabolism - Wiley Online Library
Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued - MidgardFinance.com
Novo Nordisk once-weekly insulin icodec beats Tresiba, matches Sanofi's Lantus in trials | Seeking Alpha
Novo Nordisk once weekly insulin icodec bests Tresiba in lowering blood sugar (NYSE:NVO) | Seeking Alpha
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Insulin "Icodec" Could Be a Diabetes Breakthrough with a Half Life of Over 8 Days - The Diabetes Site News
Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued - MidgardFinance.com
